Sifalimumab
Fab fragment of sifalimumab bound to IFN-α2A. From PDB: 4ypg​.
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetInterferon α
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6518H10008N1724O2032S38
Molar mass146252.08 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis.[1] It targets interferon a.[2]

Sifalimumab was developed by MedImmune; as of 2017 development had been terminated in favor of moving a competing internal product, anifrolumab, into Phase III trials.[3][4][5]

References

  1. ^ Greth W, Robbie GJ, Brohawn P, Hultquist M, Yao B (January 2017). "Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus". Immunotherapy. 9 (1): 57–70. doi:10.2217/imt-2016-0090. PMID 28000522.
  2. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab" (PDF). American Medical Association.
  3. ^ "Press release: New Hope for Lupus Patients". MedImmune. 11 August 2015. Archived from the original on 31 July 2017.
  4. ^ "Sifalimumab". AdisInsight. Springer Nature Switzerland AG. Retrieved 31 July 2017.
  5. ^ "Sifalimumab". NHS Specialist Pharmacy Service. Retrieved 31 July 2017.
Categories